Table 5. Treatment and Outcomes.
| Treatment or outcome | Patients, No. (%) (N = 31)a |
|---|---|
| Admitted | |
| Hospital | 28 (90) |
| ICU | 8 (26) |
| Hospital length of stay, median (IQR), d | 4 (3-7) |
| Highest respiratory support | |
| Room air | 4 (13) |
| Nasal cannula | 19 (61) |
| High flow nasal cannula | 5 (16) |
| Noninvasive positive pressure ventilation | 0 |
| Mechanical ventilation | 2 (7) |
| Extracorporeal membranous oxygenationb | 1 (3) |
| Treatment | |
| Steroids | 24 (77) |
| IV methylprednisolone | 16 (52) |
| Starting daily dose, median (IQR), mgc | 60 (60-156) |
| Planned duration, median (IQR), d | 7 (1-15) |
| Antibiotics | 26 (84) |
| Pulmonary function tests at follow-up, median (IQR) | |
| Predicted FEV1, % | 92 (83-104) |
| Predicted FVC, % | 99 (93-107) |
| FEV1/FVC | 84 (75-86) |
| Predicted DLCO, % | 76 (64-83) |
Abbreviations: DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICU, intensive care unit; IQR, interquartile range; IV, intravenous.
a
Percentages may not sum to 100 due to rounding.
b
One patient was supported with venovenous extracorporeal membranous oxygenation.
c
Doses expressed in milligram equivalents of prednisone.